Pharmacokinetics and tolerability of MB12066, a beta-lapachone derivative targeting NAD(P)H:quinone oxidoreductase 1: two independent, double-blind, placebo-controlled, combined single and multiple ascending dose first-in-human clinical trials

• Glavni autori: Kim S (Autor), Lee S (Autor), Cho JY (Autor), Yoon SH (Autor), Jang IJ (Autor), Yu KS (Autor)
• Format: Knjiga
• Izdano: Dove Medical Press, 2017-11-01T00:00:00Z.
• Teme: article
• Online pristup: Connect to this object online.

Seokuee Kim,1,2 SeungHwan Lee,1,3 Joo-Youn Cho,1,3 Seo Hyun Yoon,1,3 In-Jin Jang,1,3 Kyung-Sang Yu1,31Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine, 2Department of Clinical Pharmacology and Therapeutics, Samsung Medical Center, 3Department of Cli...